Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market
Author: Ken Dropiewski
SS Innovations International Performs World’s First Robotic Cardiac Telesurgeries with its SSi Mantra 3
SS Innovations International Performs World’s First Robotic Cardiac Telesurgeries with its SSi Mantra 3
ElastiMed Appoints Dr. Steve Elias to its Medical Advisory Board
YOKNEAM, Israel, Jan. 13, 2025 /PRNewswire/ — ElastiMed Ltd. a leading innovator in wearable medical devices for treating and managing lymphatic and venous diseases, is proud to announce the appointment of Dr. Steve Elias as a member of its Medical Advisory Board, effective immediately….
WindRose Health Investors Makes Strategic Investment in CIVIE
NEW YORK, Jan. 13, 2025 /PRNewswire/ — WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed a strategic investment in CIVIE (“CIVIE” or the “Company”), an AI-powered ecosystem of radiology solutions. The Company’s…
BRAIN.Q Achieves CE Mark for Its Breakthrough Therapy for Reducing Disability Following Stroke and Welcomes Stacey Pugh as Chairman of the Board
ENGLEWOOD CLIFFS, N.J., Jan. 13, 2025 /PRNewswire/ — BRAIN.Q, is excited to announce the CE Mark for its BQ 2.0 system, designed to reduce disability following ischemic stroke, the number one cause of disability worldwide. Reducing stroke disability is often achieved through endovascular…
R3 Vascular Secures WCG IRB Approval and CMS Category B Medicare Coverage for the ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
MOUNTAIN VIEW, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that it received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDE Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD). This approval allows the trial to take place at institutions that utilize WCG IRB as their central IRB in the United States. Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial.
Piccolo Medical, Inc. Announces Distribution Agreement with Spectrum Vascular
SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ — Piccolo Medical®, an emerging leader in catheter navigation devices for vascular access procedures, is proud to announce an exclusive distribution agreement with Spectrum Vascular™, a leading provider of vascular access and medication…
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
MIAMI–(BUSINESS WIRE)–Jan. 10, 2025– Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. “We are thrilled to have Paul assume […]
HFSA and Elsevier Announce Inaugural Editor-in-Chief of New Journal of Cardiac Failure-Intersections
WASHINGTON, Jan. 10, 2025 /PRNewswire/ — The Heart Failure Society of America, in partnership with Elsevier, is proud to announce the appointment of Jason N. Katz MD, MHS (NYU Grossman School of Medicine, New York, NY) as the inaugural Editor-in-Chief of Journal of Cardiac…
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery […]
Recent
Society for Vascular Surgery Annual Meeting to Unveil Cutting-Edge Research Shaping the Future of Vascular Care
Captive Radiology Secures Growth Investment to Accelerate Expansion and Enhance Patient Care Nationwide
Wolters Kluwer and Radiological Society of North America Establish 10-Year Agreement to Advance Global Access to Leading Radiology Research Journals
Popular
- No commented posts yet